Pfizer gets EU approval for Prevenar 13 for adults aged 18-49
US drug giant Pfizer (NYSE: PFE) has announced today it has received European approval for an expanded indication of its pneumococcal conjugate vaccine (PCV) Prevenar 13 (pneumococcal polysaccharide conjugate) to include adults aged 18 to 49.
The PCV is used to immunize for the prevention of invasive disease caused by vaccine-type Streptococcus pneumonia. Prevenar has been previously approved in the European Union for use in infants, young children and adolescents aged six weeks to 17 years, as well as adults 50 years of age and older.
Pfizer said Prevenar 13 is the only pneumococcal vaccine in the EU that offers protection against invasive disease from infancy through adulthood.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze